Insurance, major medical - Open Access .click

Results 201 to 210 of about 854,738 (309)

Trends in cost-related forgone care among older adults in Switzerland: a repeated cross-sectional study. [PDF]

Eur J Public Health
Jendly M +5 more
europepmc +1 more source

A goodness‐of‐fit test for regression models with discrete outcomes

Canadian Journal of Statistics, EarlyView.
Abstract Regression models are often used to analyze discrete outcomes, but classical goodness‐of‐fit tests such as those based on the deviance or Pearson's statistic can be misleading or have little power in this context. To address this issue, we propose a new test, inspired by the work of Czado et al.
Lu Yang +2 more
wiley +1 more source

Brighton Central School District and Non-Teaching Salaried Supervisors (2000) (MOA) [PDF]

, 2000

core +1 more source

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, EarlyView.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko +15 more
wiley +1 more source

Research on the Medical Insurance Payment System in the Social Security Education Industry Under Major Public Health Incidents-Taking COVID-19 as an Example

Advances in Social Science, Education and Humanities Research, 2021
openaire +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono +10 more
wiley +1 more source

Health technology assessment and medical insurance access for rare disease drugs in China: A policy review with quantitative insights from publicly available data. [PDF]

Intractable Rare Dis Res
Ai D +5 more
europepmc +1 more source

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio

Clinical Pharmacology &Therapeutics, EarlyView.
Cinnamon (Cinnamomum spp.) is used as a culinary spice and dietary supplement. A major constituent, cinnamaldehyde, was previously shown to inactivate cytochrome P450 (CYP) 2A6 in vitro. A mechanistic static model predicted an ~5‐fold increase in the AUC of the CYP2A6 substrates nicotine and letrozole.
Aiden‐Hung P. Nguyen +8 more
wiley +1 more source

Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR). [PDF]

Allergy Asthma Immunol Res
Sohn KH +8 more
europepmc +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld +9 more
wiley +1 more source

health insurance
medical insurance
insurance

moral hazard
private health insurance
pediatrics